SIMBA -- A Bayesian Decision Framework for the Identification of Optimal Biomarker Subgroups for Cancer Basket Clinical Trials

Fuente: arXiv
Saved in:
Bibliographic Details
Main Authors: Yuan, Shijie, Liu, Jiaxin, Gong, Zhihua, Qin, Xia, Qin, Crystal, Ji, Yuan, Müller, Peter
Format: Preprint
Published: 2025
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1866912382214733824
author Yuan, Shijie
Liu, Jiaxin
Gong, Zhihua
Qin, Xia
Qin, Crystal
Ji, Yuan
Müller, Peter
author_facet Yuan, Shijie
Liu, Jiaxin
Gong, Zhihua
Qin, Xia
Qin, Crystal
Ji, Yuan
Müller, Peter
contents We consider basket trials in which a biomarker-targeting drug may be efficacious for patients across different disease indications. Patients are enrolled if their cells exhibit some levels of biomarker expression. The threshold level is allowed to vary by indication. The proposed SIMBA method uses a decision framework to identify optimal biomarker subgroups (OBS) defined by an optimal biomarker threshold for each indication. The optimality is achieved through minimizing a posterior expected loss that balances estimation accuracy and investigator preference for broadly effective therapeutics. A Bayesian hierarchical model is proposed to adaptively borrow information across indications and enhance the accuracy in the estimation of the OBS. The operating characteristics of SIMBA are assessed via simulations and compared against a simplified version and an existing alternative method, both of which do not borrow information. SIMBA is expected to improve the identification of patient sub-populations that may benefit from a biomarker-driven therapeutics.
format Preprint
id arxiv_https___arxiv_org_abs_2505_13202
institution arXiv
publishDate 2025
record_format arxiv
spellingShingle SIMBA -- A Bayesian Decision Framework for the Identification of Optimal Biomarker Subgroups for Cancer Basket Clinical Trials
Yuan, Shijie
Liu, Jiaxin
Gong, Zhihua
Qin, Xia
Qin, Crystal
Ji, Yuan
Müller, Peter
Applications
Methodology
We consider basket trials in which a biomarker-targeting drug may be efficacious for patients across different disease indications. Patients are enrolled if their cells exhibit some levels of biomarker expression. The threshold level is allowed to vary by indication. The proposed SIMBA method uses a decision framework to identify optimal biomarker subgroups (OBS) defined by an optimal biomarker threshold for each indication. The optimality is achieved through minimizing a posterior expected loss that balances estimation accuracy and investigator preference for broadly effective therapeutics. A Bayesian hierarchical model is proposed to adaptively borrow information across indications and enhance the accuracy in the estimation of the OBS. The operating characteristics of SIMBA are assessed via simulations and compared against a simplified version and an existing alternative method, both of which do not borrow information. SIMBA is expected to improve the identification of patient sub-populations that may benefit from a biomarker-driven therapeutics.
title SIMBA -- A Bayesian Decision Framework for the Identification of Optimal Biomarker Subgroups for Cancer Basket Clinical Trials
topic Applications
Methodology
url https://arxiv.org/abs/2505.13202